CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector10953810.17816/22217185.2022.1.201750ОбзорыReviewsReview ArticleOptimizing therapy for cardiovascular diseases: proven organ-protective and preventive effects of pitavastatin and lercanidipine: A reviewОптимизация терапии кардиологического пациента в клинической практике: доказанные органопротективные и профилактические эффекты питавастатина и лерканидипинаhttps://orcid.org/0000-0003-2250-5942БубноваМарина ГеннадьевнаBubnovaMarina G.
Russian Federation

D. Sci. (Med.), Prof.

д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сердечно-сосудистых заболеваний

mbubnova@gnicpm.ruФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicineru29072022202213131422907202229072022Received:29072022Accepted:29072022Published:29072022Copyright ©; 2022, Eco-VectorCopyright ©; 2022, ООО "Эко-Вектор"2022Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://journals.rcsi.science/2221-7185/article/view/109538

The article aims to systematize the available data on the current use of statins and calcium channel antagonists (CA) for cardiovascular disorders therapy and to analyze the results of clinical trials focused on pitavastatin and lercanidipine. The article addresses the safety and tolerability of statins and CA and their use in the treatment of various conditions. Pharmacological features, preventive and organ-protective effects of pitavastatin and lercanidipine are described. The publications from the MEDLINE/PubMed, Scopus, Cochrane Library, eLIBRARY, and Google Scholar databases over the past 25 years were analyzed. The evidence presented in the article warrants the more extensive use of statins and CA in the treatment of patients with cardiovascular disease.

Целью настоящего обзора явилась систематизация накопленных знаний в области применения статинов и антагонистов кальциевых каналов (АК) в современной терапии кардиологического пациента и проведение анализа результатов клинических исследований с фокусом на питавастатин и лерканидипин. В статье обсуждаются вопросы назначения статинов и АК при разных клинических состояниях, безопасности и переносимости терапии. Представлены фармакологические особенности, профилактические и органопротективные эффекты питавастатина и лерканидипина. При подготовке литературного обзора проводился анализ публикаций за последние 25 лет в базах данных MEDLINE/PubMed, Scopus, Cochrane Library, eLIBRARY и Google Scholar. Представленные в статье факты свидетельствуют о необходимости более широкого применения статинов и АК при лечении сердечно-сосудистых заболеваний.

статиныпитавастатинантагонисты кальциялерканидипинсердечно-сосудистые заболеванияstatinspitavastatincalcium antagonistslercanidipinecardiovascular diseaseРусфикRUSFIC LLCCastellano JM, Fuster V, Jennings C, et al. Role of the polypill for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol. 2017;24(3S):44-51. DOI:10.1177/2047487317707324Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337. DOI:10.1093/eurheartj/ehab484Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology EUROASPIRE V survey. Eur J Prev Cardiol. 2019;26(8)824-35. DOI:10.1177/2047487318825350Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-48. DOI:10.1177/2047487315569401Medi-Voice Project, May 2008. Available at: http://cordis.europa.eu/docs/publications/1214/121407021-6_en.pdf. Accessed: 05.06.2022.Андреенко Е.Ю., Лукьянов М.М., Якушин С.С., и др. Ранняя кардиоваскулярная мультиморбидность в амбулаторной и госпитальной практике: возрастные характеристики и медикаментозное лечение пациентов (данные регистров РЕКВАЗА и РЕКВАЗА-КЛИНИКА). Кардиоваскулярная терапия и профилактика. 2020;19(5):2672 [Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Early cardiovascular multimorbidity in out- and in-patient care: age characteristics and medication therapy (data from the REKVAZA and REKVAZA-CLINIC registries). Cardiovascular Therapy and Prevention. 2020;19(5):2672 (in Russian)]. DOI:10.15829/1728-8800-2020-2672Halle M. Research in preventive cardiology: Quo vadis? Eur J Prev Cardiol. 2020;27(2)177-80. DOI:10.1177/2047487319895869Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-97. DOI:10.1001/jama.2016.13985Кухарчук В.В., Ежов М.В., Сергиенко И.В., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;38(1):7-42 [Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis. Russian Guidelines, VII. Journal of Atherosclerosis and dyslipidaemias. 2020;38(1):7-42 (in Russian)]. DOI:10.34687/2219-8202.JAD.2020.01.0002Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88. DOI:10.1093/eurheartj/ehz455Catapano AL. Pitavastatin: a different pharmacological profile. Clin Lipidol. 2012;7(3 Suppl. 1):3-9. DOI:10.2217/clp.12.21Corsini A, Bellosta S. Drug-drug interaction with statins. Exp Rev Clin Pharmacol. 2008;1(1):105-13. DOI:10.1586/17512433.1.1.105Corsini A, Ceska R. Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin. 2011;27:1551-62. DOI:10.1185/03007995.2011.589433Chan P, Shao L, Tomlinson B, et al. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2021;1:103-13. DOI:10.1080/14656566.2018.1544243Masana L. Pitavastatin − from clinical trials to clinical practice. Atheroscler Suppl. 2010;11(3):15-22. DOI:10.1016/S1567-5688(10)71065-5Аронов Д.М., Бубнова М.Г. Клиническая эффективность питавастатина. CardioСоматика. 2018;9(1):17-25 [Aronov DM, Bubnova MG. Clinical efficacy of pitevastatine. Cardiosomatics. 2018;9(1):17-25 (in Russian)].Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol. 2011;73(4):518-35. DOI:10.1111/j.1365-2125.2011.04139.xMasamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-7. DOI:10.1161/01.ATV.0000060461.64771.F0Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by Serial OCT, grayscale and integrated backscatter-IVUS. JACC Imag. 2012;5:169-77. DOI:10.1016/j.jcmg.2011.11.012Hui L, Mingjun Z, Delong L, et al. Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound. A meta-analysis. Coron Artery Dis. 2018;29(6):459-68. DOI:10.1097/MCA.0000000000000613Feng T, Huang X, Liang Q, et al. Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. Clin Ther. 2017;39:620-9. DOI.10.1016/j.clinthera.2017.01.013Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54:293-302. DOI:10.1016/j.jacc.2009.04.033Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound – the TOGETHAR trial. Circ J. 2010;74(9):1922-8. DOI:10.1253/circj.CJ-10-0038Maruyama T, Takada M, Nishibori Y, et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J. 2011;75(8):1951-9. DOI:10.1253/circj.cj-10-1163Takayama K, Taki W, Toma N, et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study–EPOCH-CAS Study. Cardiovasc Intervent Radiol. 2014;37:1436-43. DOI:10.1007/s00270-013-0813-xTaguchi I, Iimuro S, Iwata H, et al. High dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137:1997-2009. DOI:10.1161/circulationaha.117.032615Takano H, Mizuma H, Kuwabara Y, et al. The Pitavastatin Heart Failure Study (PEARL Study). Circ J. 2013;77:917-25. DOI:10.1253/circj.CJ-12-1062Kastelein J, Braamskamp M. Pitavastatin: an overview of the LIVES study. Clinical Lipidology. 2012;7(3 Suppl. 1):25-31. DOI:10.2217/CLP.12.24Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALOTM Tablet) – Drug use investigation. Available at: https://www.semanticscholar.org/paper/A-Large-scale%2C-Long-term%2C-Prospective-Surveillance-Kurihara-Douzono/8741d68b1b84b521c1113d5ffe9daefd5b979d34#paper-header/ Accessed: 05.06.2022.Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5)555-62. DOI:10.1586/erc.11.47J-PREDICT Study Group: Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (J-PREDICT). Available at: http://clinicaltrials.gov/ct2/show/NCT00301392. Accessed: 05.06.2022.Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb. 2010;17:601-9. DOI:10.5551/jat.3764Ежов М.В., Сергиенко И.В., Алексеева И.А. Питавастатин (Ливазо) в лечении дислипидемии в рутинной клинической практике. Российская программа «ЛИДЕР». Атеросклероз и дислипидемии. 2020;3(40):5-14 [Ezhov MV, Sergienko IV, Alekseeva IA. Pitavastatin (Livazo) in the treatment of dyslipidemia in routine clinical practice in Russia. Russian programme “LEADER”. Journal of Atherosclerosis and dyslipidaemias. 2020;3(40):5-14 (in Russian)]. DOI:10.34687/2219–8202.JAD.2020.03.0001Ежов М.В., Близнюк С.А., Алексеева И.А., Выгодин В.А. Распространенность гиперхолестеринемии и применения статинов в амбулаторной практике в Российской Федерации. Исследование АЙСБЕРГ – диагностирование пациентов с гиперхолестеринемией в условиях амбулаторной практики на раннем этапе с целью улучшения сердечно-сосудистого прогноза. Атеросклероз и дислипидемии. 2017;4:5-18. [Ezhov MV, Bliznyuk SA, Alekseeva IA, Vygodin VA. Prevalence of hypercholesterolemia and statins intake in the outpatient practice in the Russian Federation (ICEBERG study). Atherosclerosis and dyslipidaemias. 2017;4:5-18 (in Russian)].Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., и др. Гиполипидемическая терапия в условиях амбулаторной практики (по данным исследования АРГО-2). Рациональная Фармакотерапия в кардиологии. 2016;12(2):147-53 [Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Lipid-lowering therapy in outpatient practice (according to the ARGO-2 study). Ration Pharmacother Cardiol. 2016;12(2):147-53 (in Russian)]. DOI:10.20996/1819–6446–2016–12–2–147–153Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076 [2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076 (in Russian)]. DOI:10.15829/1560-4071-2020-4076Grassi G, Robles NR, Seravalle G, Fici F. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017;8:155-65. DOI:10.4103/jpp.JPP_34_17Остроумова О.Д., Максимов М.Л., Копченов И.И. Антагонист кальция третьего поколения лерканидипин: новые возможности в лечении артериальной гипертонии. Рациональная Фармакотерапия в Кардиологии. 2013;9(1):79-85 [Ostroumova OD, Maksimov ML, Kopchenov II. Lercanidipine, calcium channel blocker of the third generation: new possibilities in the treatment of arterial hypertension. Ration Pharmacother Cardiol. 2013;9(1):79-85 (in Russian)].Brixius K, Gross T, Tossios P, et al. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue. Clin Exp Pharmacol Physiol. 2005;32(9)708-13. DOI:10.1111/j.1440-1681.2005.04265.x.Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovasc Pharmacol. 1997;2(Suppl. 1):S19-24.Минушкина Л.О. Антагонисты кальция в лечении артериальной гипертензии:особенности лерканидипина. Российский кардиологический журнал. 2015;2(118):110-4 [Minushkina LO. Calcium antagonists in arterial hypertension treatment: specifics of lercanidipine. Rossiiskii kardiologicheskii zhurnal. 2015;2(118):110-4 (in Russian)]. DOI:10.15829/1560-4071-2015-02-110-114Barchielli M, Dolfini E, Farina P, et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol. 1997;29(Suppl. 2):S1-15. DOI:10.1097/00005344-199729002-00002Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003;16:596-9. DOI:10.1016/s0895-7061(03)00901-4Grassi G, Seravalle G, Turri C, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003;41(3):558-62. DOI:10.1161/01.HYP.0000058003.27729.5ALeonetti G, Magnani B, Pessina AC, et al. COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932-40. DOI:10.1016/s0895-7061(02)03000-5Barrios V, Navarro A, Esteras A, et al. Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press. 2002;11:95-100. DOI:10.1080/08037050211265Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens. (Greenwich). 2003;5(4)249-53. DOI:10.1111/j.1524-6175.2003.01960.xCherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003;37(3):203-12. DOI:10.1016/s0167-4943(03)00047-5Barrios V, Escobar C, Navarro A, et al. LAURA Investigators Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract. 2006;60(11):1364-70. DOI:10.1111/j.1742-1241.2006.01176.xBurnier М, Gasser UE. Efficacy and tolerability of lercanidipine in patients with arterial hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother. 2007;8:2215-23. DOI:10.1517/14656566.8.14.2215Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther. 2008;26:2-9. DOI:10.1111/j.1527-3466.2007.00035.xLund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003;21(5)1003-10. DOI:10.1097/00004872-200305000-00026Angelico P, Guarnieri N, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4 dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol. 1999;51:709-14. DOI:10.1211/0022357991772844Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens. 2002;15:94S-7S. DOI:10.1016/s0895-7061(02)02950-3Трисветова Е.Л. Оптимизация лечения лерканидипином пациентов с артериальной гипертензией и ишемической болезнью сердца. Рациональная Фармакотерапия в Кардиологии. 2014;10(3):339-45 [Trisvetova EL. Optimizing the treatment of patients with hypertension and coronary heart disease with lercanidipine. Ration Pharmacother Cardiol. 2014;10(3):339-45 (in Russian)]. DOI:10.20996/1819-6446-2014-10-3-339-345Marx A, Lichtenthal A, Milbredt C, et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens. 2004;22(Suppl. 2):S236. DOI:10.1097/00004872-200406002-00825Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1(3):173-82.Ambrosioni E, Circo A. Activity of lercanidipine administrated in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1997;29(Suppl. 2):S16-20. DOI:10.1097/00005344-199729002-00003Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1997;29(Suppl. 2):S21-5. DOI:10.1097/00005344-199729002-00004Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5,5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. J Hypertens. 1998;16(12 Pt. 1):6:1831-8. DOI:10.1097/00004872-199816120-00017Barbagallo M, Barbagallo SG. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res. 2000;12(5):375-9. DOI:10.1007/BF03339863Repine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonists vs a non-calcium antagonists hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290:2805-2. DOI:10.1001/jama.290.21.2805Zancetti A, Bond G, Henning M, et al. Emerging data on calcium channel blockers: the COHORT study. Clin Cardiol. 2003;26(Suppl. 2, II):17-20. DOI:10.1002/clc.4960261406Poncelet P, Ribstein J, Goullard L, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris). 2004;53(3):123-30. DOI:10.1016/j.ancard.2004.03.004McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs. 2000;60(5):1123-40. DOI:10.2165/00003495-200060050-00009Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006;24(1):185-92. DOI:10.1097/01.hjh.0000198987.34588.11Cleophas TJ, van Ouwekerk BM, van der Meulen J, et al. Diabetics with hypertension not controlled with ACE-inhibitors: alternate therapies. Angiology. 2001;52(7):469-75. DOI:10.1177/000331970105200705Puig JG, Calvo C, Luurila 0, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens. 2007;21(12):917-24. DOI:10.1038/sj.jhh.1002248Robles NR, Calvo C, Sobrino J, et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin. 2016;32(Suppl. 2):29-34. DOI:10.1080/03007995.2016.1218838De Ciuceis C, Salvetti M, Rossini C, et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014;32(3):565-74. DOI:10.1097/HJH.0000000000000067Derosa G, Bonaventura A, Romano D, et al. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther. 2014;39(3):277-85. DOI:10.1111/jcpt.12139Cicero A, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens. 2012;34(2):113-7. DOI:10.3109/10641963.2011.601381Speccia G, Saccaggi SP, Chezzi C, et al. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Curr Ther Res Clin Exp. 2001;62:3-15. DOI:10.1016/S0011-393X(01)80037-0Acanfora D, Gheorghiade M, Trojano L, et al. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther. 2004;11(6):423-32. DOI:10.1097/01.mjt.0000128336.62692.2fTesta R, Leonardi A, Tajana A, et al. Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev. 1997;15:187-219. DOI:1011/J.1527-3466.1997.TB00331XViviani GL. Lercanidipine in Type II Diabetic Patients With Mild to Moderate Arterial Hypertension. J Cardiovasc Pharmacol. 2002;40(1):133-9. DOI:10.1097/01.FJC.0000016321.50950.78Sabbatini M, Leonardi A, Testa R, et al. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats. Hypertension. 2000;35:775-9. DOI:10.1161/01.hyp.35.3.775Vestra MD, Pozza G, Vosca A, et al. Effect of lercanidipine compared with ramipril on albumin rate in hypertensive Type 2 diabetic with microalbuminuria: DIAL Study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab. 2004;17:259-66.Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in chronic renal failure patients: The ZAFRA Study. Renal Failure. 2005;27:73-80.Robles NR, Pastor L, Manjón M, et al. Lercanidipine in diabetic patients with renal failure. Nefrologia. 2004;24(4):338-43.Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with Lercanidipine associated with Renin-Angiotensin axis-blocking drugs. Ren Fail. 2010;32(2):192-7. DOI:10.3109/08860220903541135Bang LM, Chapman TM, Goa KL. Lercanidipine: A Reviews of its Efficacy in the Management of Hypertension. Drugs. 2003;63(22):2449-72. DOI:10.2165/00003495-200363220-00013Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-4. DOI:10.1126/science.1106830Rossoni G, Bernareggi M, De Gennaro Colonna V, et al. Lercanidipine protects the heart from low flow ischemia damage and antagonizes the vasopressor activity of endothelin-1. J Cardiovasc Pharmacol. 1997;29(Suppl. 1):S41-7. DOI:10.1097/00005344-199729001-00007Fogari R, Mugellini A, Corradi L, et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens. 2000;18(Suppl. 2):S65. DOI:10.1097/00004872-200006001-00219Campo C, Saavedra J, Segura J, et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005;96(5):365-71.Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54(2):409-13. DOI:10.1161/HYPERTENSIONAHA.109.133801Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press. 2006;15(5):268-74. DOI:10.1080/08037050600963669Cesarone M. Pressure and microcirculatory effects of treatment with lercandipine in hypertensive patients and vascular patients with hypertension. Angiol. 2000;8(Suppl. 2):S53-63. DOI:10.1177/000331970005100807Sabbatini M, Tomassoni D, Amenta F. Influence of treatment with Ca2+-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev. 2001;122:795-809.Farah R, Shurtz-Swirski R. Lercanidipine effect on polymorphonuclear leukocyte-related inflammation and insulin resistance in essential hypertension patients. Cardiol Ther. 2012;1(1):4. DOI:10.1007/s40119-012-0004-xVasigar P, Batmanabane M. Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013;4(4):238-42. DOI:10.4103/0976-500X.119707Cominacini L, Pasini AF, Pastorino AM, et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens. 1999;17:1837-41. DOI:10.1097/00004872-199917121-00009Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006;47:117-22. DOI:10.1097/01.fjc.0000196241.96759.71Martinez ML, Castro MM, Rizzi E. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol. 2008;591(1-3):224-30. DOI:10.1016/j.ejphar.2008.06.096Wu JR, Liou SF, Lin SW, et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating ras-ERK1/2 signaling. Pharmacol Res. 2009;59:48-56. DOI:10.1016/j.phrs.2008.09.015Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: A randomized, prospective crossover study. Clin Pharmacol Ther. 2002;72:302-7. DOI:10.1067/mcp.2002.127110Canavesi M, Baldini N, Leonardi A, et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol. 2004;44:416-22. DOI:10.1097/01.fjc.0000139448.56713.3dSoma MR, Natali M, Donetti E, et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol. 1998;125:1471-6. DOI:10.1038/sj.bjp.0702221Burnier M, Pruijm M, Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place the lercanidipine. Expert Opin Drug Metab Toxicol. 2009;5(8):981-7. DOI:10.1517/17425250903085135Барышникова Г.А., Чорбинская С.А., Степанова И.И. Дигидропиридиновые антагонисты кальция в лечении артериальной гипертонии у женщин: фокус на лерканидипин. Трудный пациент. 2013;11(11):10-6 [Baryshnikova GA, Chorbinskaya SA, Stepanova II. Dihydropyridine calcium antagonists for the treatment of hypertension in women: focus on lercanidipine. Difficult Patient. 2013;11(11):10-6 (in Russian)].